Production & Sales

05 May 2020
- Production & Sales
- Manufacturing
Arcturus Therapeutics, Catalent announce partnership to manufacture mRNA-based Covid-19 vaccine

By PBR Staff Writer

Arcturus Therapeutics Holdings, a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.
01 May 2020
Drug Discovery
Research & Development
Clinical Trials
Default Table Multi-Parameter Transmitter M800

By victoria.smith

The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.
30 Apr 2020
Production & Sales
Manufacturing
Catalent signs agreement with Johnson & Johnson to be US manufacturing partner for lead COVID-19 vaccine candidate

By PBR Staff Writer

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
21 Apr 2020
Production & Sales
Manufacturing
Wavelength Pharmaceuticals expands supplies of key drug ingredients for critically ill COVID-19 patients

By PBR Staff Writer

Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients (APIs), today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.
17 Apr 2020
Drug Discovery
Research & Development
Clinical Trials
5000i – Faster Scale-up of Fermentation Processes

By victoria.smith

The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.
16 Apr 2020
Production & Sales
Launches
Merck announces US launch of ONTRUZANT, a biosimilar of Herceptin

By PBR Staff Writer

Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
26 Mar 2020
Production & Sales
Marketing & Sales
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)

By PBR Staff Writer

Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases, today announced an exclusive Distribution Agreement for ONPATTRO, a first-in-class RNAi therapeutic for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy.
23 Mar 2020
Production & Sales
Marketing & Sales
Amneal accelerates distribution and production of Hydroxychloroquine Sulfate to meet potential needs of COVID-19 patients nationwide

By PBR Staff Writer

Amneal Pharmaceuticals, one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
03 Mar 2020
Production & Sales
Marketing & Sales
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

By PBR Staff Writer

AstraZeneca has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).
03 Mar 2020
Production & Sales
Marketing & Sales
Takeda completes sale of select OTC and non-core assets to Acino

By PBR Staff Writer

Takeda Pharmaceutical announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200m.

Drug Discovery

Research & Development

Apotex and Grünenthal sign deal for Nebido Canadian distribution

PrimeGen US and DT Cloud Star sign $1.5bn merger agreement

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Production & Sales

Arcturus Therapeutics, Catalent announce partnership to manufacture mRNA-based Covid-19 vaccine

Default Table Multi-Parameter Transmitter M800

Catalent signs agreement with Johnson & Johnson to be US manufacturing partner for lead COVID-19 vaccine candidate

Wavelength Pharmaceuticals expands supplies of key drug ingredients for critically ill COVID-19 patients

5000i – Faster Scale-up of Fermentation Processes

Merck announces US launch of ONTRUZANT, a biosimilar of Herceptin

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)

Amneal accelerates distribution and production of Hydroxychloroquine Sulfate to meet potential needs of COVID-19 patients nationwide

AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

Takeda completes sale of select OTC and non-core assets to Acino

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found